A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer


Condition: Prostate Cancer, Prostate Adenocarcinoma

Intervention:

  • Drug: ADT+Docetaxel+Enzalutamide

Purpose: This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer. The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated and demonstrates improved efficacy compared to ADT + docetaxel.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03246347

Sponsor: Earle Burgess

Primary Outcome Measures:

  • Measure: PSA complete response rate
  • Time Frame: 12 month
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Serologic response rate
  • Time Frame: Duration of study participation, an average of 2 years
  • Safety Issue:
  • Measure: Radiographic response rate
  • Time Frame: Duration of study participation, an average of 2-3 years
  • Safety Issue:
  • Measure: Time to castrate resistance
  • Time Frame: Duration of study participation, an average of 2 years
  • Safety Issue:
  • Measure: serologic progression free survival
  • Time Frame: Duration of study participation, an average of 2 years
  • Safety Issue:
  • Measure: radiographic progression free survival
  • Time Frame: Duration of study participation, an average of 2-3 years
  • Safety Issue:
  • Measure: overall survival
  • Time Frame: Duration of study participation, an average of 5 years
  • Safety Issue:
  • Measure: time to treatment failure
  • Time Frame: Duration of study participation, an average of 2-3 years
  • Safety Issue:
  • Measure: Treatment-related adverse events as assessed by CTCAE v4.0
  • Time Frame: Duration of study participation, an average of 5 years
  • Safety Issue:

Estimated Enrollment: 39

Study Start Date: August 21, 2017

Phase: Phase 2

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the prostate without evidence of small cell carcinoma or greater than 50% neuroendocrine differentiation. Metastatic disease must be present including soft tissue, and/or bone metastases OR nonregional lymph node involvement prior to study enrollment. If the subject has regional lymph node involvement, there must be at least one additional site of disease including visceral, non-regional nodal or skeletal metastases.
  • ADT with surgical castration with bilateral orchiectomy or medical castration with LHRH agonist or LHRH antagonist therapy may have been initiated no greater than 112 days (16 weeks) prior to enrollment date. Subjects who initiated ADT prior to consent, are not eligible if PSA has risen ≥ 25% and ≥ 2 ng/ml above nadir value since initiation of ADT prior to consent.
  • At least one PSA level of ≥ 5 ng/ml within 90 days prior to consent.
  • Prior ADT for non-metastatic disease with LHRH agonist or LHRH antagonist therapy in the neoadjuvant/adjuvant setting is permitted if: 1. Total duration of therapy did not exceed 36 months 2. 6 months have elapsed since completion of therapy prior to consent, 3. Serum testosterone > 50 ng/dl within 28 days prior to reinitiation of ADT for metastatic disease 4. Prior ADT for non-metastatic disease must have accompanied definitive local therapy for curative intent.
  • Age ≥ 18 years.
  • ECOG performance status 0-2.
  • Adequate liver function: AST and ALT <1.5x upper limit of normal, total bilirubin < 1x upper limit of normal.
  • Adequate bone marrow function: Platelets >100,000 cells/mm3, Hemoglobin > 8.0g/dL and ANC > 1,500 cells/mm3.
  • Adequate renal function with a creatinine clearance (based on Cockcroft-Gault formula) ≥ 30 mL/min.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Able to swallow and retain oral medication

Exclusion Criteria:

  • Personal history of seizure.
  • Personal history of conditions that may predispose to seizure activity including cortical cerebrovascular accident or brain trauma.
  • Known central nervous system metastases, including involvement of brain parenchyma and leptomeninges.
  • Personal history of any condition that may impair absorption of enzalutamide.
  • Prior or current therapy with ketoconazole, abiraterone, enzalutamide, apalutamide (ARN-509, JNJ-56021927), darolutamide (ODM-201, BAY1841788) or cytotoxic chemotherapy such as docetaxel, cabazitaxel, cyclophosphamide.
  • Prior therapy with bicalutamide, nilutamide or flutamide within 14 days of enrollment.
  • Within 28 days of major surgery and/or lack of recovery from prior surgical procedure or 14 days of palliative radiation prior to enrollment.
  • Prior or current therapy with an investigational agent for metastatic prostate cancer.
  • Known hypersensitivity to drugs formulated with polysorbate 80.
  • Personal history of posterior reversible encephalopathy syndrome.
  • CTCAE version 4.0 grade 2-4 peripheral sensory neuropathy.
  • Human immunodeficiency virus infection or active hepatitis B or C infection.
  • Uncontrolled and current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator.
  • Presence of any of the following within the previous 3 months prior to enrollment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.
  • History of an additional active malignancy within 12 months prior to the date of consent (except non-melanoma skin cancer).
  • Current use of strong CYP2C8 inhibitors, CYP3A4 inducers or CYP3A4, CYP2C9 or CYP2C19 substrates with a narrow therapeutic range as listed in Section 7.2.1.
  • Any condition that requires the use of prednisone > 10mg daily, or equivalent daily glucocorticoid dose, for greater than 14 days

Contact:

  • Sandra Samu-Arce, RN
  • 980-993-5484

Location:

  • Levine Cancer Institute
  • Charlotte North Carolina 28204 United States

View trial on ClinicalTrials.gov


E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe